Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Solid Biosciences Inc (NASDAQ: SLDB) closed the day trading at $4.06 down -3.68% from the previous closing price of $4.22. In other words, the price has decreased by -$3.68 from its previous closing price. On the day, 0.97 million shares were traded. SLDB stock price reached its highest trading level at $4.21 during the session, while it also had its lowest trading level at $3.79.
Ratios:
For a better understanding of SLDB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.74 and its Current Ratio is at 6.74. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Citigroup on June 26, 2025, initiated with a Buy rating and assigned the stock a target price of $14.
On January 08, 2025, Truist started tracking the stock assigning a Buy rating and target price of $16.
On December 13, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $16.Wedbush initiated its Outperform rating on December 13, 2024, with a $16 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 20 ’25 when Brooks Gabriel sold 2,895 shares for $5.96 per share. The transaction valued at 17,254 led to the insider holds 33,819 shares of the business.
Kahn Clare bought 1,860 shares of SLDB for $9,924 on Mar 11 ’25. The Director now owns 2,960 shares after completing the transaction at $5.34 per share. On Feb 19 ’25, another insider, Bain Capital Life Sciences Inv, who serves as the 10% Owner of the company, bought 1,000,000 shares for $4.03 each. As a result, the insider paid 4,030,000 and bolstered with 5,034,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLDB now has a Market Capitalization of 316315584 and an Enterprise Value of 102110568.
Stock Price History:
The Beta on a monthly basis for SLDB is 3.01, which has changed by -0.3222037 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, SLDB has reached a high of $7.37, while it has fallen to a 52-week low of $2.41. The 50-Day Moving Average of the stock is -27.03%, while the 200-Day Moving Average is calculated to be -15.21%.
Shares Statistics:
Over the past 3-months, SLDB traded about 1.08M shares per day on average, while over the past 10 days, SLDB traded about 1243850 shares per day. A total of 77.88M shares are outstanding, with a floating share count of 58.35M. Insiders hold about 25.10% of the company’s shares, while institutions hold 83.45% stake in the company. Shares short for SLDB as of 1760486400 were 9569120 with a Short Ratio of 8.87, compared to 1757894400 on 9941427. Therefore, it implies a Short% of Shares Outstanding of 9569120 and a Short% of Float of 14.6.
Earnings Estimates
Solid Biosciences Inc (SLDB) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.4 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$1.96 and -$2.93 for the fiscal current year, implying an average EPS of -$2.24. EPS for the following year is -$2.01, with 10.0 analysts recommending between -$1.56 and -$2.85.
